Transcriptome Sequencing Market

Key data points: Market size in 2027 = $6.7 billion and 2035 = $11.8 billion, growth forecast = 7.3% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in transcriptome sequencing market to 2035 by type (coding RNA and noncoding RNA), application (biomedical field and non-medical field), and region (North America, Europe, Asia Pacific, and the Rest of the World) Transcriptome Sequencing Market The future of the global transcriptome sequencing market looks promising with opportunities in the biomedical field and non-medical field markets. The global transcriptome sequencing market is expected to reach an estimated $11.8 billion by 2035 from $6.7 billion in 2027 with a CAGR of 7.3% from 2027 to 2035. The major drivers for this market are the increasing adoption of precision medicine research, the rising demand for gene expression analysis, and the growing investments in genomics research technologies. • Lucintel forecasts that, within the type category, noncoding RNA is expected to witness higher growth over the forecast period due to new interest in noncoding RNA in biology and medicine. • Within the application category, biomedical field is expected to witness higher growth over the forecast period due to more biomedical research using NGS (Next Generation Sequencing). • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more funding in genomics and improvement in sequencing infrastructure. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Transcriptome Sequencing Market Between 2025 and 2027, changes in the transcriptome sequencing market are expected to include increased adoption for routine multi-omics, declining costs for next-generation sequencing, and the development of spatial sequencing. As stated by Lucintel, market trends suggest customers are more interested in the interpretation of sequencing outputs, rather than the investment required for sequencing. • Spatial and Single Cell Transcriptomics: In the coming years, expected changes in the way biomedical research is conducted will prioritize the identification of cellular and molecular pathways and Precision Medicine. • Clinical Research: The FDA’s 2025 goals for next-generation sequencing will facilitate RNA-based oncology diagnostics. Increasingly, the goal of translational research will be the clinical interpretation of transcriptome sequencing to facilitate precision in the monitoring and evaluation of patient outcomes and the selection of optimal therapies. • Multi-omics: The integration of multiple -omics will facilitate the coordinated study of biological systems to enhance target discovery and streamline bioinformatics. • Automation and Large-Scale Analysis: Hands-on work in DNA and RNA sequencing is decreasing. Large-scale sequencing companies are actively marketing services to process thousands of samples. Operational scale will further decrease the cost of transcriptome sequencing. This will make transcriptome sequencing available for the biopharmaceutical and population health markets. • Agricultural and Environmental Markets: The use of RNA sequencing to analyze stress response in crops is expected to increase with the estimated global population of 9.7 billion by the year 2050. RNA sequencing will allow plant breeders to improve crops and make selected traits more resilient to the environment. The development of tools and the focus on technologies that increase the overall capacity to perform and analyze sequencing will provide opportunities for innovation in the field and enable adoption by researchers in life sciences and biomedicine. Regulatory and reimbursement barriers will continue to exist, as will the challenges of ensuring the reliability and trust of data; however, these will not hinder market growth. Recent Developments in the Transcriptome Sequencing Market The transcriptome sequencing market has experienced rapid growth driven by technological advancements, increasing demand for personalized medicine, and expanding applications across research and clinical settings. As the field evolves, several key developments have emerged, shaping the future landscape of transcriptome analysis. These developments are enhancing data accuracy, reducing costs, and broadening accessibility, thereby accelerating research and clinical diagnostics. Understanding these trends is crucial for stakeholders aiming to capitalize on emerging opportunities and navigate challenges in this dynamic market. • Technological Innovations: Introduction of long-read sequencing platforms like Oxford Nanopore and PacBio has improved transcriptome analysis by enabling more accurate detection of isoforms and structural variations, thus enhancing data quality and depth. • Cost Reduction Strategies: Advances in sequencing chemistry and automation have significantly lowered costs, making transcriptome sequencing more accessible to academic institutions and smaller biotech firms, thereby expanding market reach. • Integration of AI and Machine Learning: Incorporation of AI algorithms for data analysis has increased the speed and accuracy of transcriptome data interpretation, facilitating faster insights and reducing manual effort. • Clinical Applications Expansion: Growing use of transcriptome sequencing in diagnostics, especially for cancer and rare genetic disorders, has driven market growth by demonstrating clinical utility and improving patient outcomes. • Regulatory and Standardization Efforts: Development of standardized protocols and regulatory guidelines has improved data reproducibility and reliability, fostering greater acceptance of transcriptome sequencing in clinical settings. These developments are collectively transforming the transcriptome sequencing market by improving technological capabilities, reducing costs, and expanding clinical applications. As a result, the market is experiencing accelerated growth, increased adoption across research and healthcare sectors, and a broader scope for innovative applications, positioning it for sustained expansion in the coming years. Strategic Growth Opportunities in the Transcriptome Sequencing Market Booming demand for faster and cost effective sequencing to meet the requirements of functional biology and single cell research has fueled the growth of the transcriptome sequencing market. Beyond 2026, other auxiliary and associated fields such as translational research, artificial intelligence (AI) and decentralized testing will promote the growth of this market. Lucintel expects that in the upcoming years, advancement in applications of the technology will drive market growth as compared to the sale of instruments. • Use of Spatial Transcriptomics: The requirement to understand and analyze interactions between genes and tissues in biological samples has promoted the use of spatial transcriptomics. 10x Genomics’ Visium product has gained enormous popularity in biomarker discovery and drug development. • Clinical Biomarker Discovery: Use of transcriptomics has gained prominence in companion diagnostics to select the appropriate therapy for a patient based on the type of cancer. Several companies have received regulatory approvals for their in-vitro diagnostic tests. This presents a lucrative opportunity for clinical biotech companies to launch regulated RNA-based testing services. • Long Read Isoform Analysis: Long read sequencing has applications in analysis of alternative pre-mRNA splicing and fusion transcripts. In April 2025, PacBio launched its long read sequencing system to offer 90 billion bases per run. This will benefit research and quality control (QC) in the field of rare diseases, cancers and gene therapies. • Animal and Plant Genetics: Research shows producers can enhance their agriculture businesses by using omics data for breeding to improve traits related to feed efficiency and resistance to diseases. As of March 2025, the Food and Agriculture Organization of the United Nations (FAO) reported that global agricultural production and sustainable agriculture are two critical challenges for the food industry. The FAO further stated that by the year 2050, global food production must increase by 50%. Providers of omics data can assist and collaborate with seed and livestock producers and aquaculture businesses. • Cloud Computing: Many of the smaller laboratories do not have enough personnel to focus on computing. Therefore, there is a demand for cloud-based services for bioinformatics. In June 2025, the National Institutes of Health (NIH) reported that the All of Us Research Program, a major research initiative in the United States, enrolled over 750,000 participants. Other service centers can handle this type of work and reduce barriers for end users. Omics data integration and service centric models can facilitate expansion of transcriptome sequencing. Long read and spatial omics data can increase average revenue per sample and broaden market acceptance. Vendors can establish recurring business by reducing the cost of analysis for omics data and validating clinical biomarkers. Trans integration of omics data in clinical and life sciences can facilitate rapid and widespread adoption. Transcriptome Sequencing Market Drivers and Challenges Trends such as the growing body of research, advancements in technology, and expanding clinical adoption will likely propel the transcriptome sequencing market in the foreseeable future. Of course, market conditions can restrict growth. From a business standpoint, how stringent are regulations on data? How flexible are regulations regarding use of data? What is the competition like? These will all impact market growth. From a scientific and technical standpoint, what is the ability and willingness of the market to invest in infrastructure Lucintel believes that the market will remain focused on investing in innovative technologies, and that the ability to integrate these technologies into the research and clinical workflow in an affordable and sustainable manner will remain the focus of market development. The factors responsible for driving this market include: • Increased Demand for Precision Medicine: Because transformation of genomics into actionable clinical insights remains a developing field, researchers are focused on other avenues for clinical medicine. For example, the American Association for Cancer Research reports that as of 2025, the field of oncology will continue to enlist the integrative analysis of transcriptomics in an effort to discern prognosis, therapeutic response, and tumor subtype. The same momentum is gaining in the fields of neurology and immunology. • Improvements in Transcriptomics: Long-read sequencing, spatiotemporal transcriptomics, and new computation methods will increase our understanding of biological systems. Advances in single-cell methods and greater automation in the next 3-5 years will make transcriptome sequencing more accessible. These will allow us to study previously inaccessible biological questions. Lower error rates and increased automation will also make the technology accessible to more researchers. The power of this technology to study biological systems will also encourage its use in clinical research to develop new diagnostic and therapeutic tools. • Rising Importance of Transcriptomics in Clinical Research: Better access to transcriptomic data and large-scale omics research will facilitate the validation of biopharmaceutical targets and help stratify patients for clinical trials. Transcriptomic studies will also be used to gain a deeper understanding of the mechanisms of action of a drug and evaluate side effects. New legislation and reimbursement policies will create a more favorable business environment for transcriptomics and other omics-related research. This, in addition to the increased understanding of biological systems, will encourage the use of these technologies to assess patients, design clinical trials, and evaluate the effectiveness of therapies. • Increased Research Investments and Infrastructure Development: Increasing public and private investments in biobanks, the cloud, and other genomics and population health science research infrastructure continue to grow. In September 2025, there were large-scale initiatives that initiated work to build resource and data infrastructure to study population health and disease. Researchers in all sectors will benefit from centralized and standardized laboratory resources to perform large-scale genomic sequencing. It is expected that publicly funded projects will promote and foster collaboration across the academic, clinical, and industry sectors to achieve the goals of large-scale and transformative transcriptomic research. Further, advancements in research infrastructure and resources are expected to decrease the costs and increase the ease of genomic research, and facilitate the creation of population-specific and disease-specific reference transcriptomes. • Declining Costs and Improved Efficiency: Because of various technical improvements, performing transcriptomic research is expected to become less expensive, especially if combined with other omics studies. Further, higher sample throughput and lower reagent, storage and instrument costs increase the feasibility of transcriptomic research and decrease barriers to entry for CROs, academic labs and other biotech companies. The challenges facing this market include: • High Cost and Complexity of Data: Large and heterogeneous data sets, such as those generated by transcriptome sequencing, create a dependency on advanced computing infrastructure and bioinformatics. Large single-cell transcriptome sequencing experiments are expected to generate millions of sequencing reads in the next few years. These large datasets increase the burden on storage and computing infrastructure, and may encourage small and medium biomedical institutes to outsource these services. Specifications in sample and sequencing protocols and differences in annotation and statistical methods may lead to equivocal findings. In the next 3-5 years, advances in bioinformatics and automated software may allow easier integration of transcriptome data to draw biomedical and clinical conclusions. • Lack of Regulatory and Reimbursement Frameworks: The lack of regulatory and reimbursement frameworks creates uncertainty around the clinical validity and legal admissibility of transcriptome-based sequencing. In July 2025, the sequencing of transcriptomes was primarily done in the context of research and early clinical trials. Safety and efficiency of the procedures as well as the reproducibility of the results are some of the main criteria for wide-spread acceptance of transcriptome sequencing in the clinical field. In the 2025-2030 outlook, the same situation is expected; absence of regulatory frameworks may reduce investment and product commercialization in this field. • Sample Quality, Standardization and Labor Shortages: RNA is fragile and deteriorates over time. As of November 2025, several laboratory processes still relied on stringent controls on the temperature of the environment, the reagents, and other components. In addition, several processes had to be performed within a few hours of sample collection. Beyond the limited availability of trained personnel in molecular and bioinformatics, the lack of standardization of processes, the training of personnel, and automation of processes will pose challenges for performing large transcriptome studies. The expansion of the transcriptome sequencing market will be driven by the rise of precision and personalized medicine. Increased collaboration between public and private entities will improve the economic and technological infrastructure of the life sciences, and advance research, drug development and diagnostics. Progress in transcriptome technology will occur at the pace of development of standardized and automated processes that improve clinical and research outcomes and control data security. Integration of advanced clinical, bioinformatics and data science knowledge will be essential to harness the power of sequencing technologies. Companies that are best positioned to provide automated, scalable and reliable transcriptome services will excel in the market. List of Transcriptome Sequencing Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies transcriptome sequencing market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the transcriptome sequencing market companies profiled in this report include- • Illumina • Thermo Fisher Scientific • Eurofins Scientific • Roche • Bio-Rad Transcriptome Sequencing Market by Segment The study includes a forecast for the global transcriptome sequencing market by type, application, and region. Transcriptome Sequencing Market by Type [Value ($B) from 2019 to 2035]: • Coding RNA • Noncoding RNA Transcriptome Sequencing Market by Application [Value ($B) from 2019 to 2035]: • Biomedical Field • Non-medical Field Transcriptome Sequencing Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Transcriptome Sequencing Market The development and integration of spatial and long-read sequencing technology is rapidly changing the landscape of transcriptome sequencing. Between 2025 and 2027, increased instrumentation, reagent and partnership opportunities will be coupled with greater governmental funding for national and regional genomics resources. New technology offerings and changes in customer priorities will be tracked by Lucintel. • United States: Further development of transcriptome technologies was tracked by Lucintel. For example, in January 2025, 10x Genomics increased the multiplexing of its Xenium Prime assay from 1K to 5K, facilitating the spatial transcriptome analysis of approximately 5,000 genes. Greater assay multiplexing will increase the use of transcriptome technologies in biomedical research, including oncology and neuroscience. • China: Lucintel reported that, in March 2025, the BGI Group announced that more than 10,000 of its DNBSEQ sequencing systems were installed worldwide, and that the Group’s collaborations expanded the use of next-generation sequencing in clinical research and other areas. • Germany: German research facilities continued collaborating with EU programs. In February 2025, the EMBL outlined plans to develop its existing facilities to include advanced techniques in single-cell and spatial transcriptomics. Between now and 2030, Germany will be able to use the European Research Infrastructure and engage in transnational and multisite studies using standardized transcriptomic data. • India: The Genome India initiative further developed India’s public genomics infrastructure. In January 2025, the Indian Biological Data unit released 10,000 whole genome sequences. While the sequences are of no immediate use in transcriptomics, they are relevant because they provide a resource to study the genetic basis of biological processes in India and aid in the development of diagnostic assays. • Japan: The Japanese Ministry of Health, Labor and Welfare continued expanding public and private partnerships to improve sequencing capacities. In April 2025, RIKEN published research based on single cell analysis and transcriptomics. In the coming years, transcriptomic data generated by public and private initiatives will be relevant to support basic and pharmaceutical research. Features of the Global Transcriptome Sequencing Market Market Size Estimates: transcriptome sequencing market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: transcriptome sequencing market size by type, application, and region in terms of value ($B). Regional Analysis: transcriptome sequencing market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the transcriptome sequencing market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the transcriptome sequencing market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the transcriptome sequencing market by type (coding RNA and noncoding RNA), application (biomedical field and non-medical field), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?